Novo Nordisk A / S produces and markets pharmaceutical products and services. Since its founding in Denmark in 1923, the company has developed into a leading company in the diabetes sector worldwide.
According to Novo Nordisk's latest financial reports the company's current earnings are โน51.37 Billion. In 2025 the company made an earning of โน2.005 Trillion, an increase over its 2024 earnings that were of โน1.887 Trillion. The earnings displayed on this page is the company's Pretax Income.